ライフサイエンスコーパス: antimetastatic

1 (CAI) (NSC609974) is both antiangiogenic and antimetastatic.

2 However, the mechanism of the antimetastatic actions of KiSS1 and its G-protein-couple

3 umor immune responses that provide effective antimetastatic activities in preclinical studies.

4 ckade of PD-1/PD-L interactions enhanced the antimetastatic activities of alphaGalCer.

5 otentiated the antitumor, anti-invasive, and antimetastatic activities of docetaxel both in culture a

6 molecules bearing the tumor-sensitizing and antimetastatic activities of TAT-RasGAP317-326.

7 nhibitor that has both antiproliferative and antimetastatic activities.

8 Sunitinib maintained its antiangiogenic and antimetastatic activity but lost its direct antitumor ef

9 ally type I NKT cells, inhibit liver NK-cell antimetastatic activity by the production of IL-10.

10 iral pyrrolidines with antiproliferative and antimetastatic activity in a murine model of colon carci

11 ferred NKT cells dramatically enhanced their antimetastatic activity in mice.

12 using a monoclonal antibody (2G8) has potent antimetastatic activity in orthotopic human tumor xenogr

13 DX-8951f also demonstrated antimetastatic activity in the late-stage model, signifi

14 factors and displayed improved antitumor and antimetastatic activity in vivo compared with the earlie

15 The antimetastatic activity is epitope specific, as another

16 Taken together, our findings illustrate the antimetastatic activity of 6BIO on the basis of its abil

17 Furthermore, the profound antimetastatic activity of NK cells was equally effectiv

18 Potential mechanisms for antimetastatic activity of synthetic glycoamines may inc

19 The significant antimetastatic activity of synthetic glycoamines was det

20 n CS-682-treated animals correlated with the antimetastatic activity of this compound.

21 sting that each gene appeared to produce its antimetastatic activity through a common antiangiogenic

22 bited experimental lung metastasis, and this antimetastatic activity was compromised in mice depleted

23 was dependent on CD8(+) T cells, whereas its antimetastatic activity was dependent on host CD73 expre

24 asculature resulted in a 15-fold increase in antimetastatic activity without producing drug-associate

25 ontain other bioactive ingredients that have antimetastatic activity.

26 meric CQ (pCQ) as a macromolecular drug with antimetastatic activity.

27 T) shows potent and selective anticancer and antimetastatic activity.

28 HSCN-NH2 may be a potent antitumorigenic and antimetastatic agent for postsurgical use prior to exten

29 s high-affinity TFD100 should be a promising antimetastatic agent for the treatment of various cancer

30 e demonstrated that CS-682 is an efficacious antimetastatic agent that significantly prolongs surviva

31 nt for tumor suppression and functions as an antimetastatic agent.

32 The III1-C peptide is an antiangiogenic and antimetastatic agent.

33 tential of Ap44mSe as a selective anticancer/antimetastatic agent.

34 lanation directly supporting genistein as an antimetastatic agent.

35 ical applications as potential antitumor and antimetastatic agent.

36 omo-indirubin-3'-oxime (6BIO) as a promising antimetastatic agent.

37 ell migration and their implied potential as antimetastatic agents for human cancers has garnered sig

38 oprine and related compounds could be potent antimetastatic agents for Vav1-positive pancreatic tumor

39 ted deaths, but the development of effective antimetastatic agents has been hampered by the paucity o

40 st that these analogs have promise as potent antimetastatic agents in lung cancer.

41 Critical assessment of these antimetastatic agents is warranted, because they may def

42 and suggest that HAS2 inhibitors can act as antimetastatic agents that disrupt a paracrine growth fa

43 for future drug combination approaches with antimetastatic agents to improve outcomes and reduce res

44 re highly sought as potential anticancer and antimetastatic agents.

45 o the potential utility of p38 inhibitors as antimetastatic agents.

46 uld also improve the screening efficiency of antimetastatic agents.

47 ns for TLR5 agonists as hepatoprotective and antimetastatic agents.

48 and as orally active, bioavailable, and safe antimetastatic agents.

49 been an important lead in the development of antimetastatic agents.

50 with 4a in vivo on mice, suggesting putative antimetastatic and analgesic activities of this compound

51 In conclusion, S247 demonstrated significant antimetastatic and antiangiogenic activity and impaired

52 acin, might have therapeutic applications as antimetastatic and antiangiogenic agents.

53 suggest that ROCK inhibitors would be useful antimetastatic and antiangiogenic chemotherapeutic agent

54 performed to characterize the effects of an antimetastatic and antiangiogenic molecule, carboxyamido

55 of intracellular signaling and exhibits both antimetastatic and antitumorigenic properties.

56 polyamine component and was shown to be both antimetastatic and cytotoxic to human L3.6pl pancreatic

57 l candidate function underlying the putative antimetastatic and oncogenic activities of NM23-H1.

58 rough binding to the CT element and that its antimetastatic and other reported functions are likely d

59 nth., Rutaceae), exhibits antiproliferative, antimetastatic, and apoptotic activities through a poorl

60 multifunctional serpin with antitumorigenic, antimetastatic, and differentiating activities.

61 as also recognized by a previously described antimetastatic antibody, mAb 1A5.

62 t that inhibition of MET may be an effective antimetastatic approach to treat cancers with p53 mutati

63 organ, and discusses opportunities for novel antimetastatic approaches for cancer therapy.

64 e lung by tumor-secreted chemokines build an antimetastatic barrier with loss of neutrophil chemokine

65 alloproteinase (MMP) inhibitors has hindered antimetastatic cancer drug discovery.

66 Ks are therefore a promising drug target for antimetastatic cancer treatments that could supplement a

67 ortant therapeutic target for development of antimetastatic cancer treatments.

68 The selective antitumor and antimetastatic chelator di-2-pyridylketone 4,4-dimethyl-

69 which there is a pressing need to find novel antimetastatic compounds.

70 results permit the conformational design of antimetastatic disintegrins.

71 veloped an animal model suited to evaluating antimetastatic drug efficacy.

72 We also used the device to screen antimetastatic drugs for their inhibition of mesenchymal

73 es, a specific category of anti-invasion and antimetastatic drugs is missing.

74 human PCa metastasis well suited for testing antimetastatic drugs.

75 zyme B in vivo, strongly suggesting that the antimetastatic effect of A2A blockade was due to enhance

76 However, the antimetastatic effect of AdCMVIFN-beta was not directly

77 In contrast to the antimetastatic effect of AMG487, local growth of 66.1 ma

78 lecular evidence that is associated with the antimetastatic effect of berberine by showing a nearly c

79 f a CD8(+) T-cell response, which exert both antimetastatic effect of entolimod and establishment of

80 nd ROCK are additional key components of the antimetastatic effect of kisspeptins.

81 The IL-2 mutant shows a higher antimetastatic effect than does wtIL-2 in several transp

82 that combined therapy also had a more potent antimetastatic effect than each modality alone.

83 itro suggesting a possible mechanism for the antimetastatic effect.

84 stasis, targeted delivery of Dox produced an antimetastatic effect.

85 ent corresponded to a significantly enhanced antimetastatic effect: lung nodules were reduced by 7- t

86 Antimetastatic effects along with stimulation of NK cell

87 Because its antimetastatic effects are mediated by binding to VEC ra

88 Many of their antimetastatic effects could be the result of their abil

89 D40 Ab resulted in substantial antitumor and antimetastatic effects in three tumor models.

90 show that miR-520f exerts anti-invasive and antimetastatic effects in vitro and in vivo, warranting

91 in vitro, and that MN-15 and MN-3 Fabs have antimetastatic effects in vivo, resulting in improved su

92 ls by anti-asialo GM1 antibody abrogated the antimetastatic effects of AdCMVIFN-beta.

93 RDX, and RhoA was capable of overriding the antimetastatic effects of ectopically expressed miR-31 i

94 Thus, the potent antimetastatic effects of GRN163L may be related, in par

95 hether the apoptotic, antiproliferative, and antimetastatic effects of guggulsterone (GS), a farnesoi

96 The antivascular, antitumor, and antimetastatic effects of mpJX-594 were amplified by con

97 Our study supports the hypothesis that the antimetastatic effects of zoledronic acid may be through

98 MMP9 appear to mediate the antiinvasive and antimetastatic effects produced by FKBP gene expression.

99 These antitumor and antimetastatic effects were comparable with those result

100 tos-1-yl)-L-leucine did not have significant antimetastatic effects, and no reduction in metastasis i

101 le, and manifest complementary antitumor and antimetastatic effects.

102 E-cad-positive cells, the IGF-IR may produce antimetastatic effects.

103 which can produce significant antitumor and antimetastatic effects.

104 ellular immunity that may have antitumor and antimetastatic effects.

105 ellular matrix and to its reported antitumor/antimetastatic effects.

106 trioxifene represents a SERM with potential antimetastatic efficacy for the treatment of androgen-in

107 Studies of antimetastatic efficacy in man are warranted and are und

108 concentrations of genistein associated with antimetastatic efficacy in preclinical models are achiev

109 The antimetastatic efficacy of CS-682 and its p.o. availabil

110 also provide initial preclinical data on the antimetastatic efficacy of recently discovered small-mol

111 We determined the antitumor and antimetastatic efficacy of the camptothecin analogue DX-

112 Studies on the antimetastatic function of KiSS1 and GPR54 largely focus

113 ty group AT-hook 2 gene (HMGA2) mediates the antimetastatic function of TTF-1.

114 Gr-1(int) myeloid cells that promote NK cell antimetastatic function.

115 ring mice to identify novel antiinvasive and antimetastatic functions for Fkbp8, and subsequently for

116 mental evidence that CAV1 may function as an antimetastatic gene in malignant melanoma.

117 equired for stimulation of the antitumor and antimetastatic immune response by B7.2-IgG/TC.

118 t antiproliferative, prodifferentiating, and antimetastatic/invasive effects on prostatic epithelial

119 EMSY amplification and miR-31 expression, an antimetastatic microRNA, in the METABRIC cohort of human

120 exerts its metastatic potential by silencing antimetastatic miR-200 through direct targeting of the T

121 demethylation of a regulatory region of the antimetastatic miRNA cluster mir-200ba429, leading to th

122 Surprisingly, the antimetastatic outcome of MMP9 ablation seemed to be dep

123 dditional depletion of NK cells reverts this antimetastatic phenotype.

124 To evaluate the antimetastatic potential of genistein, we developed an a

125 In the current study, we investigated the antimetastatic potential of penfluridol, an antipsychoti

126 Antimetastatic properties of covalently inactivated VIIa

127 The antitumor and antimetastatic properties of SCF may be useful in treati

128 al are known to possess antiproliferative or antimetastatic properties.

129 th anti-inflammatory, antiproliferative, and antimetastatic properties.

130 flammatory, immunoregulatory, antitumor, and antimetastatic properties.

131 tastasis is essential for the development of antimetastatic regimens.

132 iltrating activated NK cells and an enhanced antimetastatic response.

133 p53 (TP53) family member p63 (TP63) plays an antimetastatic role through its minor epithelial isoform

134 iating cells need to overcome organ-specific antimetastatic signals in order to undergo reactivation.

135 reby stimulating its ability to activate the antimetastatic small GTPase RhoB.

136 rug platform suitable for use in combination antimetastatic strategies and potential use in cytoplasm

137 ase progression and an attractive target for antimetastatic strategies to reduce colon cancer mortali

138 fy TNFalpha and TGFbeta1 dual blockade as an antimetastatic strategy in solid tumors.

139 asis but might be targeted by curcumin as an antimetastatic strategy.

140 cell invasion, and may provide an important antimetastatic target.

141 tastasis in animal model systems and suggest antimetastatic therapeutic potential of the TbetaRI-I.

142 eutrophil protease-Tsp-1 axis as a potential antimetastatic therapeutic target.

143 rtality, there nonetheless remains a lack of antimetastatic therapies that are clinically available.

144 er metastasis and suggest new strategies for antimetastatic therapies that target the beta-adrenergic

145 may serve as targets for antiangiogenic and antimetastatic therapies.

146 represents a promising molecular target for antimetastatic therapies.

147 ion opening the opportunity to develop novel antimetastatic therapies.

148 nce knowledge about metastasis and candidate antimetastatic therapies.

149 are prometastatic and represent targets for antimetastatic therapies.

150 screening strategies needed to develop novel antimetastatic therapies.

151 tudy, we provide preclinical evidence for an antimetastatic therapy based on targeting integrin beta3

152 e activity represents a promising target for antimetastatic therapy for several types of tumor.

153 antagonists may offer significant value for antimetastatic therapy in patients with colon cancer.

154 lopment of anti-FGFR inhibitors as potential antimetastatic therapy.

155 tastasis and identify a potential target for antimetastatic therapy.

156 ociated isoforms are potential candidates in antimetastatic therapy.

157 ssion and a promising therapeutic target for antimetastatic therapy.

158 se signaling pathways could prove useful for antimetastatic therapy.

159 ms and may become markers and/or targets for antimetastatic therapy.

160 d heparanase and reciprocal up-regulation of antimetastatic tissue inhibitors of matrix metalloprotei

161 Two examples include the antimetastatic, tumor suppressor genes, desmocollin 3 (D

162 a polymeric form of fibronectin is strongly antimetastatic when administered systemically to tumor-b